[
  {
    "ts": null,
    "headline": "Here's Why You Should Retain Ecolab Stock in Your Portfolio Now",
    "summary": "ECL's robust product lineup, innovation-driven growth and strong Q2 results underscore its long-term potential despite macroeconomic headwinds.",
    "url": "https://finnhub.io/api/news?id=7fc89de8486eeb24152abc8148fd9b30760a2b4b68f5981ea01a06c0d69c7da0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769621700,
      "headline": "Here's Why You Should Retain Ecolab Stock in Your Portfolio Now",
      "id": 138287596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ECL's robust product lineup, innovation-driven growth and strong Q2 results underscore its long-term potential despite macroeconomic headwinds.",
      "url": "https://finnhub.io/api/news?id=7fc89de8486eeb24152abc8148fd9b30760a2b4b68f5981ea01a06c0d69c7da0"
    }
  },
  {
    "ts": null,
    "headline": "OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System",
    "summary": "Outset Medical stock jumps after FDA clears next-gen Tablo dialysis system, the first to meet the agency's latest cybersecurity standards.",
    "url": "https://finnhub.io/api/news?id=0da895aed845d712d8201953ba003782bd3b802329a9c846b9a16f2e8ae4fce9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769621460,
      "headline": "OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System",
      "id": 138287597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Outset Medical stock jumps after FDA clears next-gen Tablo dialysis system, the first to meet the agency's latest cybersecurity standards.",
      "url": "https://finnhub.io/api/news?id=0da895aed845d712d8201953ba003782bd3b802329a9c846b9a16f2e8ae4fce9"
    }
  },
  {
    "ts": null,
    "headline": "QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform",
    "summary": "QTIH teams up with Olea Medical to add advanced visualization and quantitative analytics to its cloud imaging platform, lifting shares.",
    "url": "https://finnhub.io/api/news?id=a8ec6f0417f8519c6f0df40489a24a0a72e4a2f735496bf7e76763e71bf594c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769617560,
      "headline": "QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform",
      "id": 138285237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "QTIH teams up with Olea Medical to add advanced visualization and quantitative analytics to its cloud imaging platform, lifting shares.",
      "url": "https://finnhub.io/api/news?id=a8ec6f0417f8519c6f0df40489a24a0a72e4a2f735496bf7e76763e71bf594c8"
    }
  },
  {
    "ts": null,
    "headline": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
    "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
    "url": "https://finnhub.io/api/news?id=eb9505c9f5e354b3b6eeb6affd67156d88e0d5832f9c41472c2cbfa42b650038",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612880,
      "headline": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
      "id": 138281541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
      "url": "https://finnhub.io/api/news?id=eb9505c9f5e354b3b6eeb6affd67156d88e0d5832f9c41472c2cbfa42b650038"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corporation (BSX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $93.61 as of January 27th. BSX’s trailing and forward P/E were 50.06 and 26.95 respectively according to Yahoo Finance. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. BSX presents a tac",
    "url": "https://finnhub.io/api/news?id=dac08ff5b29fc88e0b5a405cd133c6ddb52df2e503391ad30c99313c88d6407b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769609086,
      "headline": "Boston Scientific Corporation (BSX): A Bull Case Theory",
      "id": 138280951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific Corporation’s share was trading at $93.61 as of January 27th. BSX’s trailing and forward P/E were 50.06 and 26.95 respectively according to Yahoo Finance. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. BSX presents a tac",
      "url": "https://finnhub.io/api/news?id=dac08ff5b29fc88e0b5a405cd133c6ddb52df2e503391ad30c99313c88d6407b"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Retain Baxter International Stock in Your Portfolio Now",
    "summary": "BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.",
    "url": "https://finnhub.io/api/news?id=416bd4bc90efb0ec5f8dfb7a45810c12887f1aac80e5953a9c85ce89f78d2b9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769606640,
      "headline": "Reasons to Retain Baxter International Stock in Your Portfolio Now",
      "id": 138281611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.",
      "url": "https://finnhub.io/api/news?id=416bd4bc90efb0ec5f8dfb7a45810c12887f1aac80e5953a9c85ce89f78d2b9b"
    }
  },
  {
    "ts": null,
    "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
    "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
    "url": "https://finnhub.io/api/news?id=6b8a19271e13128fe728d51e5b8d54bebed410a56a5e704297fc82c93e769414",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769603220,
      "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
      "id": 138281612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
      "url": "https://finnhub.io/api/news?id=6b8a19271e13128fe728d51e5b8d54bebed410a56a5e704297fc82c93e769414"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Boston Scientific (BSX) Valuation After The Penumbra Deal And Recent Share Moves",
    "summary": "Boston Scientific stock snapshot after recent moves Boston Scientific (BSX) has seen mixed returns recently, with the share price close to US$93.61 after a modest gain over the past week but declines over the past month and past 3 months. See our latest analysis for Boston Scientific. That recent short term share price weakness, with a 30 day share price return of a 2.55% decline and a 90 day share price return of a 6.67% decline, sits against a three year total shareholder return of 102.40%...",
    "url": "https://finnhub.io/api/news?id=c51e91ed5cdbc504474b215a812e92c1545afebedd10d15204780de109497c74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769559709,
      "headline": "Assessing Boston Scientific (BSX) Valuation After The Penumbra Deal And Recent Share Moves",
      "id": 138277147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific stock snapshot after recent moves Boston Scientific (BSX) has seen mixed returns recently, with the share price close to US$93.61 after a modest gain over the past week but declines over the past month and past 3 months. See our latest analysis for Boston Scientific. That recent short term share price weakness, with a 30 day share price return of a 2.55% decline and a 90 day share price return of a 6.67% decline, sits against a three year total shareholder return of 102.40%...",
      "url": "https://finnhub.io/api/news?id=c51e91ed5cdbc504474b215a812e92c1545afebedd10d15204780de109497c74"
    }
  }
]